EUCTR2018-001715-79-DE进行中（未招募）1 期
A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma – The GENESIS Study - BL-8040 with G-CSF for Stem Cell Mobilization in multiple myeloma - The GENESIS Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 207
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must be between the ages of 18 and 78 years.
- •2. Patients must have a signed study informed consent prior to entering the study.
- •3. Histologically confirmed Multiple Myeloma prior to enrollment
- •4. At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
- •5. Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator’s discretion.
- •6. The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
- •7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- •8. Adequate organ function at screening as defined below:
- •a. Hematology:
- •White blood cell counts more than 2.5 x 10^9/L
- •Absolute neutrophil count more than 1.5 x 10^9/L
- •Platelet count more than 100 x10^9/L
- •b. Renal Function:
- •GFR value of =15 mL/min/1.73^2 calculated by MDRD equation
- •c. Hepatic function:
- •ALT and/or AST = 2.5 x ULN
- •Total Bilirubin = 2.0 x ULN unless the subject has Gilbert disease
- •d. Coagulation test:
- •INR or PT: =1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •aPTT: =1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •9. Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative urine/serum pregnancy test within 72 hours prior to G-CSF first administration.
- •10. Women of childbearing potential must agree to use 2 methods of effective contraception: One barrier method (e.g. diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method, unless she uses a highly effective method. Highly effective methods of contraception include:
- •Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
- •Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
- •Intrauterine device (IUD)
- •Intrauterine hormone-releasing system (IUS)
- •Bilateral tubal occlusion
- •Vasectomised partner
- •Sexual abstinence
- •These methods must be used prior to study entry and for the duration of study participation through 30 days after the last dose of study treatment. Non-childbearing potential is defined as (by other than medical reasons):
- •=45 years of age and has not had menses for over 2 years.
- •Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a Follicle Stimulating Hormone (FSH) value in the postmenopausal range upon pre-trial (screening) evaluation.
- •Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 weeks prior to screening. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure; otherwise the subject must be willing to use two adequate barrier methods throughout the study, starting with the Screening Visit, through 30 da
排除标准
- •1. Previous history of autologous or allogeneic-HCT.
- •2. Failed previous HSC collections or collection attempts.
- •3. Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
- •a. Dexamethasone: 7 days
- •b. Thalidomide: 7 days
- •c. Lenalidomide: 7 days
- •d. Pamolidomide: 7 days
- •e. Bortezomib: 7 days
- •f. Carfilzomib: 7 days
- •g. G-CSF: 14 days
- •h. GM-CSF or Neulasta®: 21 days
- •i. Erythropoietin or erythrocyte stimulating agents: 30 days
- •j. Eltrombopag, romiplostim or platelet stimulating agents: 30 days
- •k. Carmustine (BCNU): 42 days/6 weeks
- •l. Daratumumab: 28 days
- •m. Ixazomib: 7 days
- •4. Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
- •5. Received >8 cycles of alkylating agent combinations
- •6. Received > 6 cycles of melphalan.
- •7. Received prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).
- •8. Received prior treatment with venetoclax
- •9. Plans to receive maintenance treatment within 60 days post- transplantation (e.g. lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
- •10. Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
- •11. Known active CNS metastases or carcinomatous meningitis.
- •12. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
- •13. Has an active infection requiring systemic therapy or uncontrolled infection.
- •14. Has a known additional malignancy that is progressing or requires active treatment.
- •15. Has an underlying medical condition that would preclude study participation.
- •16. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •17. O2 saturation < 92% (on room air).
- •18. Personal history or family history of Long QT Syndrome or Torsade de Pointes
- •19. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
- •20. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Angina Pectoris Class >2 or NYHA Heart Failure Class >2.
- •21. ECG at screening showing QTcF > 470 msec and/or PR > 280 msec.
- •22. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
- •23. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- •24. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •25. Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception as detailed above, within the projected duration of the trial, starting with the Screening Visit through 30 days after the last dose of
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644